LXX.CN - Lexaria Bioscience Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.8900
-0.0500 (-5.32%)
At close: 3:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.9400
Open0.9400
Bid0.8800 x 0
Ask0.9200 x 0
Day's Range0.8700 - 0.9400
52 Week Range0.8300 - 2.6900
Volume11,205
Avg. Volume51,470
Market Cap71.62M
Beta (3Y Monthly)4.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / September 17, 2019 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.

  • GlobeNewswire

    Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery

    While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset.

  • ACCESSWIRE

    Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

    KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 - “Stable ready-to-drink beverage compositions comprising lipophilic active agents”. Lexaria’s patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia. This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” announced on August 15, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.

  • ACCESSWIRE

    Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

    KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECHTM for fast, effective delivery. Long known as a technology innovator, Lexaria delivers patented processes within every serving of ChrgD+ to improve the consumer experience of hemp oil with CBD. ChrgD+ uses the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils.

  • ACCESSWIRE

    Lexaria Bioscience Announces it has Received Four New Patents

    KELOWNA, BC / ACCESSWIRE / August 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted.

  • ACCESSWIRE

    Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

    KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated. Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing.

  • ACCESSWIRE

    Lexaria Bioscience Receives Cannabis R&D License from Health Canada

    KELOWNA, BC / ACCESSWIRE / August 13, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed. Lexaria’s new cannabis R&D license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.

  • ACCESSWIRE

    Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

    KELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, announces the successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECHTM technology. A primary goal of the R&D Program was to determine whether Lexaria’s DehydraTECH technology causes the formation of a new molecular entity (“NME”) through its processing.

  • ACCESSWIRE

    Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

    KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines. Integra partners with select underexposed and undervalued emerging growth company and leverages decades of market experience with a robust proprietary database to continuously maximize market visibility throughout their clients’ different development cycles. Integra is being engaged for an initial six-month contract and will receive US$12,500 per month and a total of 150,000 restricted common shares of the Company.

  • ACCESSWIRE

    Lexaria Bioscience Summarizes its Eleven Technology Licenses

    KELOWNA, BC / ACCESSWIRE / July 30, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” said Chris Bunka, Chief Executive Officer. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous.

  • ACCESSWIRE

    Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership

    Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide. Manufacturing will be done at Hill Street’s soon to be acquired OneLeaf Cannabis cultivation and processing facility in Regina, Saskatchewan, pending licensing by Health Canada.

  • CNW Group

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • ACCESSWIRE

    Lexaria Bioscience Enters CBD License Agreement with Universal Hemp

    KELOWNA, BC / ACCESSWIRE / July 11, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp., to provide Lexaria’s patented DehydraTECHTM technology to Universal Hemp LLC, a B2B manufacturing company of high-performing hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries, for utilization into many CBD-based food ingredients to be produced and sold across the USA immediately, and in Canada when regulations permit. Competitive financial details including royalty rates remain confidential and undisclosed although the companies have agreed to disclose minimum payments over the life of the agreement of US$3,750,000.

  • ACCESSWIRE

    Lexaria Bioscience Enters CBD Beverage License Agreement with Nic’s Beverages

    KELOWNA, BC / ACCESSWIRE / July 10, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria’s patented DehydraTECHTM technology to Nic’s Beverages L.L.C. for use in CBD-based beverages to be produced and sold throughout the United States.

  • PR Newswire

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • ACCESSWIRE

    Lexaria Announces 2019 Annual and Special Meeting Results

    KELOWNA, BC / ACCESSWIRE / June 21, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2019 Annual and Special Meeting ...

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

    NEW YORK, June 13, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled,.

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements

    NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • ACCESSWIRE

    Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents

    New Enhanced DehydraTECH™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations. KELOWNA, BC / ACCESSWIRE / June 4, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECH™ delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. The Company has filed new patent applications related to the recent innovations.

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

    Consider what [Lexaria BioScience Corp.’s DehydraTECH] technology could mean for the CBD edibles space. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Discussing Disruptive Potential of CBD Delivery Technology

    NEW YORK, May 30, 2019 -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire.

  • ACCESSWIRE

    Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

    KELOWNA, BC / ACCESSWIRE / May 28, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria's DehydraTECHTM delivery technology with generic nanotech techniques delivers 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. On March 20, 2019, Lexaria announced it was beginning a series of animal studies with multiple objectives that included developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier ("BBB") to enter brain tissue.

  • ACCESSWIRE

    Lexaria Bioscience and Nuka Enterprises' 1906 Expand Cannabis Product Relationship

    KELOWNA, BC / ACCESSWIRE / May 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), an innovator in drug delivery platforms, today announced the most reliable fast acting edibles on the market will now be available across the country through a major expansion in operations by Nuka Enterprises LLC, ("Nuka") maker of 1906 cannabis edibles for high functioning adults. Last year, Nuka acquired contractual options to expand its use of DehydraTECHTM technology. Exercising some of those options, Nuka plans to expand operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020.